<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 53-year-old man with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease was treated with conventional <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CyA), because of refractory bilateral <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Immediately following the conversion from conventional CyA to a microemulsion formulation, he presented with neurological complications </plain></SENT>
<SENT sid="2" pm="."><plain>The neurological findings, pleocytosis of the cerebrospinal fluid (CSF) and brainstem lesions revealed by brain magnetic resonance imaging (MRI) suggested neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease </plain></SENT>
<SENT sid="3" pm="."><plain>After discontinuing CyA and introducing oral <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, the neurological symptoms, pleocytosis of CSF and brainstem lesions on MRI improved </plain></SENT>
<SENT sid="4" pm="."><plain>Although the microemulsion formulation, which can maintain a stable level of blood CyA, is a useful agent for the control of ocular lesions in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease, the resulting abrupt increase in blood CyA level may have induced neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease </plain></SENT>
</text></document>